DepoTech Corp. said it has completed a $7.3 million round ofventure financing, led by Burr, Egan, Deleage & Co., andBrentwood Associates. Other major investors included DSVVentures, the Walden Group, Sorrento Ventures, and thecompany's initial investor, Sanderling.
La Jolla, Calif.-based DepoTech, a privately held developer ofsystems for sustained-release drug delivery, said the proceedswill be used to expand research and development aimed atimproved delivery of oncology drugs, therapeutic proteins andanti-infectives.
(c) 1997 American Health Consultants. All rights reserved.